Quick Answer
CRISPR Therapeutics AG reported Stockholders Equity of $1.92 billion for fiscal year 2025.
CRISPR Therapeutics AG Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $1.92B | -0.5% |
| 2024 | $1.93B | +2.6% |
| 2023 | $1.88B | +0.4% |
| 2022 | $1.88B | -21.8% |
| 2021 | $2.40B | +44.2% |
| 2020 | $1.66B | +77.2% |
| 2019 | $939.42M | +139.5% |
| 2018 | $392.19M | +108.8% |
| 2017 | $187.83M | -19.3% |
| 2016 | $232.85M | +900.2% |
| 2015 | -$29.10M | -317.2% |
| 2014 | -$6.97M | -1100.3% |
| 2013 | -$581.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.92B | -1.2% | +12.0% |
| June 30, 2025 | $1.71B | -13.6% | -6.5% |
| March 31, 2025 | $1.83B | -12.2% | -5.3% |
| December 31, 2024 | $1.93B | +2.6% | -0.4% |
| September 30, 2024 | $1.94B | +12.3% | -2.1% |
| June 30, 2024 | $1.98B | +9.1% | -4.9% |
| March 31, 2024 | $2.08B | +12.3% | +10.7% |
| December 31, 2023 | $1.88B | +0.4% | +9.0% |
- CRISPR Therapeutics AG showed a decrease of -0.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2025 period, CRISPR Therapeutics AG’s stockholders equity has grown by 330876.8% (from -$581.0 thousand to $1.92 billion).
- The most recent figure is from CRISPR Therapeutics AG’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: